iDFS strongly correlates with OS in HR+/HER2- early breast cancer, supporting its use as a surrogate endpoint in trials.
HR Breast Cancer
Advertisement
Imlunestrant with or without abemaciclib improved PFS in ER+/HER2- advanced breast cancer post-endocrine therapy.
Final results from the PENELOPE-B trial show palbociclib did not improve survival in high-risk HR+/HER2– breast cancer.
Camizestrant plus CDK4/6 inhibition significantly improved PFS in HR+/HER2– advanced breast cancer with ESR1 mutations.
The study used SEER data of nearly 20,000 cases.
People diagnosed with metastatic breast cancer have a notably increased risk of developing heart disease.
The CDK4/6 inhibitor showed meaningful improvement in HR+, HER+ disease.
New research suggests ICI therapy improves efficacy outcomes in early-stage breast cancer over adjuvant therapy.
The Breast Cancer Index assists in decision-making regarding adjuvant endocrine therapy for hormone receptor-positive BC.
Dr. Mik Rinne discusses a study on the efficacy of the CDK2 inhibitor BLU-222 in patients with HR+/HER2- breast cancer.
Dr. Margaret Gatti-Mays details the treatment options for BC patients in the hormone receptor-positive metastatic setting.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.